がん治療・がん免疫療法「癌樹状細胞療法」のセレンクリニック／リンク集

1.�Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998, 4: 328-332.

2.�Chakraborty NG, et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother. 1998, 47: 58-64.

3.�Thurner B, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999, 190: 1669-1678.

4.�Panelli MC, et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma- associated antigens MART-1 and gp100. J Immunother. 2000, 23: 487-498.

5.�Mackensen A, et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000, 86: 385-392.

6.�Schuler-Thurner B, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000, 165: 3492-3496.

7.�Triozzi PL, et al. Intratumoural injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 2000, 89 (12): 2646-2654.

8.�Trefzer U, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer. 2000, 85: 618-626.

9. Banchereau J, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001, 61: 6451-6458.

10. Toungouz M, et al. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors. J Leukoc Biol. 2001, 69: 937-943.

11.�Lau R, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother. 2001, 24: 66-78.

12. Jonuleit H, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001, 93: 243-251.

13.�Andersen MH, et al. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int J Cancer. 2001, 94: 820-824.

14.�Chang AE, et al. A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer. Clin Cancer Res. 2002, 8: 1021-1032.

15.�Schuler-Thurner B, et al. Rapid induction of tumor-specific type1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002, 195 (10): 1279-1288.

16. Krause SW, et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. Journal of Immunotherapy 2002, 25 (5): 421-428.

17.�Smithers M. et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother. 2003, 52: 41-52.

18.�O’Rourke MGE, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003, 52: 387-395.

19. Slingluff C, et al. Clinical and Immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003, 21 (21): 4016-26.

20.�Bedrosian I, et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. Journal of Clinical Oncology. 2003, 21 (20): 3826-3835.

21.�Nagayama H, et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res. 2003, 13 (5): 521-530.

22. de Vries IJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003, 9(14): 5091-100.

23.�Hersey P, et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother. 2004, 5 (2): 125-134.

24. Trefzer U, et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer. 2004, 110: 730-740.

25. Di Nicola M, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+ derived dendirtic cell vaccination: A phase I trialin metastatic melanoma. Clinical cancer Research. 2004, 10: 5381-5390.

26. Vilella R, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterogenous melanoma cell line lysate. Cancer Immunol Immunother. 2004, 53: 651-658.

27. Haenssle HA, et al. Hybrid cell vaccination in metastatic melanoma: Clinical and immunolgic results of a phase I/II study. Journal of Immunotherapy. 2004, 27 (2): 147-155.

28.�Trefzer U, et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine. 2005, 23: 2367-2373.

29. Akiyama Y, et al. Clinical pesponse in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. Journal of Translational Medicine. 2005, 3: 4-13.

30. Banchereau J, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells from CD34+ progenitors and activated with type I interfereon. J Immunother. 2005, 28 (5): 505-516.

31. Linette GP et al. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clinical Cancer Research. 2005, 11(21): 7692-9.

32. Escobar A, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005, 42(3): 555-68.

33. Joseph W F, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells. Cancer Immunol Immunother. Cancer Immunol Immunother. 2005, 6: 1-10.

34. Homma S, et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur J Clin Invest. 2005, 35(4): 279-86.

35. de Vries IJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005, 23(24): 5779-87.

36. Goto S, et al. Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma. Anticancer Res. 2005, 25: 3741-3746.

37. Wei Y, et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol. 2006, 28: 585-93.

38. Ridolfi R, et al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med.2006. 4: :36-